Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs
- PMID: 27737644
- PMCID: PMC5064800
- DOI: 10.1186/s12866-016-0852-y
Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs
Abstract
Background: Leptospirosis is an important reemerging zoonosis, with more than half a million cases reported annually, and is caused by pathogenic Leptospira species. Development of a universal vaccine is one of the major strategic goals to overcome the disease burden of leptospirosis. In this study, a chimeric multi-epitope protein-based vaccine was designed and tested for its potency to induce a specific immune response and provide protection against L. interrogans infection.
Results: The protein, containing four repeats of six T- and B-cell combined epitopes from the leptospiral outer membrane proteins, OmpL1, LipL32 and LipL21, was expressed and purified. Western blot analysis showed that the recombinant protein (named r4R) mainly expressed in a soluble pattern, and reacted with antibodies raised in rabbit against heat-killed Leptospira and in guinea pigs against the r4R vaccine. Microscopic agglutination tests showed that r4R antisera was immunological cross-reactive with a range of Chinese standard reference strains of Leptospira belonging to different serogroups. In guinea pigs, the r4R vaccine induced a Th1-biased immune response, as reflected by the IgG2a/IgG1 ratio and cytokine production of stimulated splenocytes derived from immunized animals. Finally, r4R-immunized guinea pigs showed increased survival of lethal Leptospira challenges compared with PBS-immunized animals and tissue damage and leptospiral colonization of the kidney were reduced.
Conclusions: The multi-epitope chimeric r4R protein is a promising antigen for the development of a universal cross-reactive vaccine against leptospirosis.
Keywords: Cross protection; Leptospira; Multi-epitope; Outer membrane protein; Vaccine.
Figures
Similar articles
-
Identification of immunodominant B- and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of Leptospira interrogans.Clin Vaccine Immunol. 2010 May;17(5):778-83. doi: 10.1128/CVI.00405-09. Epub 2010 Mar 17. Clin Vaccine Immunol. 2010. PMID: 20237196 Free PMC article.
-
Protection of guinea pigs against Leptospira interrogans serovar Lai by LipL21 DNA vaccine.Cell Mol Immunol. 2008 Oct;5(5):385-91. doi: 10.1038/cmi.2008.48. Cell Mol Immunol. 2008. PMID: 18954563 Free PMC article.
-
Protein typing of major outer membrane lipoproteins from Chinese pathogenic Leptospira spp. and characterization of their immunogenicity.Vaccine. 2009 Dec 10;28(1):243-55. doi: 10.1016/j.vaccine.2009.09.089. Epub 2009 Sep 29. Vaccine. 2009. PMID: 19796723
-
Vaccines against leptospirosis.Curr Top Microbiol Immunol. 2015;387:251-72. doi: 10.1007/978-3-662-45059-8_10. Curr Top Microbiol Immunol. 2015. PMID: 25388138 Review.
-
Expansion of the in vitro assay for Leptospira potency testing to other serovars: case study with Leptospira Hardjo.Biologicals. 2013 Sep;41(5):323-4. doi: 10.1016/j.biologicals.2013.06.003. Epub 2013 Jul 6. Biologicals. 2013. PMID: 23838569 Review.
Cited by
-
Chimeric proteins of Mycoplasma hyopneumoniae as vaccine and preclinical model for immunological evaluation.Braz J Microbiol. 2024 Mar;55(1):943-953. doi: 10.1007/s42770-023-01240-7. Epub 2024 Jan 13. Braz J Microbiol. 2024. PMID: 38217795
-
Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.Pathogens. 2023 May 31;12(6):787. doi: 10.3390/pathogens12060787. Pathogens. 2023. PMID: 37375478 Free PMC article. Review.
-
Sph2(176-191) and Sph2(446-459): Identification of B-Cell Linear Epitopes in Sphingomyelinase 2 (Sph2), Naturally Recognized by Patients Infected by Pathogenic Leptospires.Vaccines (Basel). 2023 Feb 4;11(2):359. doi: 10.3390/vaccines11020359. Vaccines (Basel). 2023. PMID: 36851237 Free PMC article.
-
Analysis of LruC lipoprotein and identification of peptides candidates for vaccine development and diagnosis of leptospirosis.PLoS One. 2023 Feb 6;18(2):e0281344. doi: 10.1371/journal.pone.0281344. eCollection 2023. PLoS One. 2023. PMID: 36745643 Free PMC article.
-
Challenges for the development of a universal vaccine against leptospirosis revealed by the evaluation of 22 vaccine candidates.Front Cell Infect Microbiol. 2022 Oct 7;12:940966. doi: 10.3389/fcimb.2022.940966. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36275031 Free PMC article.
References
-
- Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, Gilman RH, Willig MR, Gotuzzo E, Vinetz JM. Peru-United States Leptospirosis Consortium. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757–771. doi: 10.1016/S1473-3099(03)00830-2. - DOI - PubMed
-
- Faine S, Adher B, Bloin C, Perolat P. Leptospira and leptospirosis. 2. Melbourne: MedSci; 1999.
-
- Yan J, Dai BM, Yu ES. Leptospirosis. 3. Beijing: People’s Medical Publishing House; 2006.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
